We at HHS are working with President Trump on a comprehensive plan to bring down the high price of prescription drugs.
Whether there is spec buying or not is not the greatest factor in the high cost of pharmaceuticals.
I'd never have guessed that, six years after Medicare introduced a drug benefit, it would still be forbidden to negotiate prices with pharmaceutical companies. Health reform might fix that, but it probably won't.
The rising cost of prescription drugs has sparked a prairie fire that is spreading across our nation.
To drive down high drug costs, we need to shine a light on the negotiations between drug manufacturers, middleman negotiators and pharmacies.
One of the biggest factors fueling the angst over drug prices in the U.S. is that some older medicines that should be sold cheaply as generics are still priced very high, often owing to a dwindling number of generic competitors and the rising cost of producing these drugs.
When we find unjustified spikes in the prices of long-standing life-saving drugs, we should slap penalties on companies trying to cheat people who need those drugs!
It's crucial to keep in mind that the hundreds of millions of dollars now spent on prescription drug advertisements are ultimately paid for by consumers in the form a higher drug prices.
With the skyrocketing costs of prescription drugs, American taxpayers shouldn't be footing the bill for medicine going to waste.
The status quo on prescription drug prices is deeply broken and unsustainable.
There are no issues more personal than prescription drugs and the high prices Americans must pay to get the medicine they need.
I support negotiating authority to lower prescription drug prices.
The pricing of a pharmaceutical product is opaque and frustrating, especially for patients.
If the U.S. can transform its domestic market for HIV/AIDS drugs, it will certainly transform the world market and make HIV/AIDS drugs more affordable for everyone, everywhere.
